Close Menu

Missing From Trials

African-American patients are missing out on cancer drug clinical trial opportunities, Stat News and ProPublica report. Their analysis of US Food and Drug Administration data found that for most trials for cancer drugs approved since 2015, fewer than 5 percent of the patients who participated were African American, even as African Americans make up 13.4 percent of the US population.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.